Pazorest 200 mg is a chemotherapy medication prescription that contains Pazopanib, an active oral tyrosine kinase inhibitor (TKI), for the treatment of specified cancers. It is typically prescribed for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have previously undergone chemotherapy. Pazorest 200 mg works by suppressing the growth of cancer cells and suppressing the tumor growth by ending their blood supply.

The active component Pazopanib in Pazorest is a multi-targeted TKI that acts on several receptors that are implicated in tumor growth and neovascularization (new blood vessel formation), including:

VEGFR-1, VEGFR-2, VEGFR-3 (Vascular Endothelial Growth Factor Receptors)

PDGFR-α and PDGFR-β (Platelet-Derived Growth Factor Receptors)

c-KIT and FGFR (Fibroblast Growth Factor Receptors)

By inhibiting these crucial routes, Pazorest denies the tumors the oxygen and nutrients that they require for growth and metastasis. This makes it particularly effective in cancers that are highly reliant on vascular networks for survival and expansion.

Pazorest 200 mg is utilized primarily in the following scenarios:

Advanced Renal Cell Carcinoma (RCC)

Often utilized as a first-line treatment or in intolerant patients to other therapies.

It offers a specific treatment with an acceptable side-effect profile. 

Advanced Soft Tissue Sarcoma (STS)

Indicated for those patients who have already undergone chemotherapy.

Suits best in the case of non-adipocytic soft tissue sarcomas.

The usual starting dose of Pazorest is 800 mg once daily on an empty stomach, which may be achieved by taking a number of 200 mg tablets as required. However, the dose may be adjusted based on patient response and tolerance. The tablets should be swallowed whole, not crushed or chewed, to maintain drug efficacy.

Oral formulation: Provides convenience compared to intravenous cancer therapies.

Targeted action: Attacks cancer-specific targets with less impact on normal cells.

Slows disease growth: Clinical trials have shown slowed tumor growth and more prolonged progression-free survival in the majority of patients.

Flexible dosing: Allows clinicians to tailor the regimen according to tolerability.

Like all anti-cancer treatments, Pazorest can cause side effects. Commonly occurring adverse reactions include

Diarrhea

Elevated blood pressure (hypertension)

Fatigue

Nausea and vomiting

Loss of appetite

Hair or skin color changes

Liver enzyme elevations

Significant but rare risks are liver toxicity, cardiac arrhythmias (QT prolongation), bleeding, and delayed wound healing. Liver function tests at the beginning and during treatment are advisable.

Precautions

Do not use during pregnancy and breastfeeding.

Monitor patients with underlying liver disease carefully.

Avoid grapefruit juice as it raises the drug's blood level.

Encourage patient to inform about all medications consumed, especially liver enzyme and heart function-changer drugs.

In clinical trials, Pazopanib has been quite effective in terms of enhancing progression-free survival in metastatic RCC and advanced STS-treated patients. It is firmly established in oncology treatment guidelines and offers a balance of efficacy with tolerable side effects for the majority of patients.

Store Pazorest 200 mg tablets at room temperature, in an area where it is not exposed to direct sunlight and moisture. Avoid exposing the drug to children. Do not use after the expiration date shown on the package.

Pazorest 200 mg (Pazopanib) is an immense leap in the management of some aggressive cancers. With its oral targeted therapy status, patients are able to enjoy enhanced quality of life, convenience of treatment, and chances for longer survival. However, like with any strong medicine, it must be administered only by a skilled oncologist under vigilant monitoring to ensure safety and efficacy.